503A Compounded
Compounded Hair and Scalp Formulations
Formulary reviewed by Benn Bluestein-Veyra, M.Sc. Organic Chemistry · Founder, ExaVeyra Sciences
Four scalp solutions and one oral tablet, prepared against a prescription for an individual patient. Selection, suitability and counselling are prescriber matters; this page covers what the pharmacy can prepare and how it is dated.
The defining procurement fact in this category is that its beyond-use dating is not uniform. Three of the five entries are dated far shorter than the fourth, and the per-fill ceilings move with them.
Supply and documentation
- Lead time
- 3 to 5 business days from order to delivery, covering both preparation and transit.
- Coverage
- licensed in 33+ states, with licensure confirmed for your destination before a first order ships
- Testing
- Endotoxin and sterility testing on every sterile batch
- Compounded under USP General Chapters 795, 797 and 800
- FDA-registered, GMP-compliant supplier sourcing, with no gray-market material
- Lot identification and the assigned beyond-use date on every container label
- Documentation package matched to what Tennessee Public Chapter 1016 asks of a supplier: particle counts, lot-specific sterility reporting and a Certificate of Analysis
- Certificates of Analysis are documented and lot-specific, held on file with the tissue bank and the pharmacy for your records.
- Account registration in 24 to 48 hours for licensed clinics and practitioners
- Same-day quotes
- Orders placed with the pharmacy within 24 hours of approval
- A dedicated account manager for each practice
ExaVeyra exists to simplify access to biologics, molecules and medical devices through one point of contact, so a practice runs one account rather than three.
- Every formulary page is checked by a chemist. ExaVeyra was founded by an M.Sc. organic chemist, and specification data is verified against the source catalogue rather than reproduced from a vendor sheet.
- When Tennessee became the first state to write exosome documentation into statute, it asked for particle counts, a viscosity report and a lot-specific Certificate of Analysis. That is the package we already supply against.
- One verified account covers biologics, 503A compounded formulations and devices, with a single account manager rather than a separate vendor relationship for each.
Formulary
Available Formulations
What the pharmacy can prepare. This is not a dosing recommendation, and it does not indicate suitability for any patient.
GHK-Cu 1%
Hair Restoration Solution
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| Solution 30 mL | 35 days | Max 1 unit |
Minoxidil 5% / Finasteride 0.1%
Solution
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 60 mL | 35 days | Max 1 unit |
Minoxidil 5% / Tretinoin 0.025%
Solution
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 60 mL | 180 days | Up to 5 units |
Minoxidil 5% / Azelaic Acid 12.5% / Finasteride 0.1% / Ketoconazole 2%
Solution
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 60 mL | 35 days | Max 1 unit |
Finasteride
Tablet
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 1 mg | Per prescription | Per prescription |
| 5 mg | Per prescription | Per prescription |
The dating split is the thing to plan around
Most categories in this catalogue share one dating profile. This one does not. Three entries carry a short beyond-use date with a single-unit ceiling per fill, while one solution carries the long date and a five-unit ceiling. The oral tablet is dated per prescription instead.
That asymmetry is worth planning around. The short-dated entries move on their own clock, so they reorder on their own line rather than alongside the long-dated solution. Setting that up once keeps every unit arriving with useful life ahead of it.
Read the table per row
The beyond-use date and the per-fill ceiling are stated for each entry separately in this category, and they differ. Each row carries its own, so read them per entry.
Topical and oral finasteride are different products
Finasteride appears twice in this category in materially different forms. It is present as a component at a fraction of a percent in two of the scalp solutions, and separately as an oral tablet in two strengths. Those are not variants of one another and they are not dated the same way.
Practices ordering both should hold them as separate line items with separate records. The prescriber determines which is appropriate for a given patient, and the pharmacy prepares what the prescription specifies.
What the solutions contain
- A minoxidil and finasteride combination at 5 percent and 0.1 percent, in 60 mL.
- A minoxidil and tretinoin combination at 5 percent and 0.025 percent, in 60 mL.
- A four-active combination adding azelaic acid at 12.5 percent and ketoconazole at 2 percent to the minoxidil and finasteride base, in 60 mL.
- A copper tripeptide solution at 1 percent, in 30 mL, which is the only entry here not built on minoxidil.
Percentages are fixed per formulation and are not selectable at order time. The four-active solution is the most complex preparation in the catalogue by component count, which is reflected in both its dating and its per-fill ceiling.
Container formats and storage
The minoxidil combinations are supplied in 60 mL, the copper tripeptide solution in 30 mL, and the tablet by count. Store as stated on the container label. None of these are cold chain. Keep them in the supplied container so the lot record and the dating on the label stay intact.
The prescribing information for oral finasteride states that it is not indicated for use in women, and sets out the warnings and adverse reactions a prescriber is expected to review before prescribing. [1]
FDA notes that compounded drugs are not reviewed by the agency for safety, quality or labelling before they reach patients, which is why the prescriber and the pharmacy carry that responsibility between them. [2]
Ordering
Accounts are opened to NPI-verified licensed practitioners. Each preparation is dispensed against a prescription for an individual patient, so ordering runs through the pharmacy rather than as stock purchasing, and quantity per fill is bounded by the limits shown for each entry. Wholesale pricing is released once an account is verified.
The shortest limit governs
Assigned beyond-use date, product stability, in-use and puncture dating, the prescribed directions, pharmacy policy and pharmacist review all apply at once, and whichever expires first is the one that counts.
Sources
- DailyMed, FINASTERIDE tablet prescribing information (accessed 2026-08-09)
- FDA, Understanding the Risks of Compounded Drugs (accessed 2026-08-09)
Verified practitioner access
Request the full formulary and pricing
The pages on this site list a representative selection. Verified practitioners receive the complete named formulary, current wholesale pricing, available strengths and formats, and the identity and credentials of the compounding pharmacy that prepares each preparation.
Access requires a valid NPI. Compounded formulations are prepared by our 503A pharmacy partner, a compounding pharmacy licensed by the Texas State Board of Pharmacy. We verify the number against the national registry before an account is opened, which is why pricing is not published openly: these are prescription preparations supplied to licensed practices rather than consumer products.
Already verified? Sign in to the provider portal
Compounded medications are not FDA-approved finished drug products. Preparations are dispensed against a prescription for a named patient. Nothing on this page is medical advice or a recommendation for any patient.
Equipo de Cumplimiento e Investigación
Hable con Nuestro Equipo de Cumplimiento
Nuestro equipo puede guiarlo a través del contexto de investigación, preguntas sobre el suministro y consideraciones regulatorias. Seleccione las áreas de interés y lo conectaremos con el especialista adecuado.
Áreas de interés marque todas las que correspondan
Todas las consultas son revisadas por nuestro equipo de cumplimiento e investigación. No compartimos su información con terceros.
Frequently asked questions
- Why do some entries here allow only one unit per fill?
- The per-fill ceiling tracks the beyond-use date, so every unit arrives with useful life ahead of it. The figure for each entry is in the table.
- Can the four-active solution be prepared without one component?
- Modified formulations are assessed case by case. Send the change you need to your account manager and the pharmacy will confirm whether it can compound and document it.
- Is the copper tripeptide solution interchangeable with the cosmeceutical creams?
- They are different preparations: a different concentration, a different vehicle and a different container size. The cosmeceutical topicals are a separate category with their own table.
- What is the regulatory status of these formulations?
- Compounded medications are not FDA-approved finished drug products. They are prepared under section 503A of the Federal Food, Drug, and Cosmetic Act against a prescription for an individual patient, which is a separate regulatory pathway rather than a lesser version of the same one.
- What documentation ships with an order?
- Lot identification on the container label, with a Certificate of Analysis available on request. Practices with their own documentation requirements should raise them at account setup so the pharmacy can confirm what it is able to supply.
- Who can open an account?
- NPI-verified licensed practitioners. Verification happens before pricing is released, and licensure is confirmed for the destination state before a first order ships.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved and are prepared by a licensed 503A compounding pharmacy per individual patient prescription. Formulations are supplied to NPI-verified licensed practitioners only. A Certificate of Analysis and lot documentation are available on request. Nothing on this page is medical advice, a dosing recommendation, or a statement that any formulation is suitable for a given patient. Selection of any formulation in this category, including counselling on the labelling that applies to its components, is the responsibility of the prescribing practitioner.
Reviewed 2026-08-09 by Benn Bluestein-Veyra, M.Sc. Organic Chemistry, founder, exaveyra sciences. Specifications on this page are transcribed from the pharmacy formulary and checked line by line against the source catalogue.